Response rate falls for Idera's TLR9 agonist plus Yervoy combo in melanoma

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) reported updated data showing that tilsotolimod (IMO-2125) plus Yervoy ipilimumab led to a lower overall response rate (ORR) in metastatic melanoma patients than what the company reported at this year's American Society of Clinical Oncology (ASCO) meeting.

At June's ASCO meeting, Idera reported data from 21 evaluable metastatic melanoma patients who progressed on anti-PD-1 therapy in the Phase II portion of the Phase I/II ILLUMINATE-204 (2125-204) trial showing that 8 mg/kg intratumoral tilsotolimod plus anti-CTLA-4 mAb Yervoy led to a confirmed ORR of 38.1% per RECIST criteria, including two complete responses and six partial responses (see "Idera's TLR9 Agonist Plus Yervoy Leads to 38% ORR in Melanoma")...